2025 Annual Meeting Abstract Submissions

Oral Clinical Research (human subjects) includes:

• Studies involving more than 20 human subjects (>20 subjects)

These oral presentation submissions should consist of rigorous clinical or scientific investigations with a formal design; scientific literature-based foundation; detailed material and methods sections; statistical data analysis; and other objective conclusions based on the data presented.

Presenters are allotted 15 minutes for each presentation, followed by five minutes of discussion.

All Oral Research and Clinical Innovations presentations are scheduled for Friday, March 28, 2025.

Submissions not accepted for Oral Research Presentations will be eligible for presentation as an ePoster.

Oral Scientific Research (non-human subjects) includes:

• Animal studies
• Research studies performed on cell lines
• Material studies
• Microbiological studies
• Benchtop research

Both of these oral presentation submissions should consist of rigorous clinical or scientific investigations with a formal design; scientific literature-based foundation; detailed material and methods sections; statistical data analysis; and other objective conclusions based on the data presented.

Presenters are allotted 15 minutes for each presentation, followed by five minutes of discussion.

All Oral Research and Clinical Innovations presentations are scheduled for Friday, March 28, 2025.

Submissions not accepted for Oral Research Presentations will be eligible for presentation as an ePoster.

Clinical Innovations Includes:

• Original, novel and thoughtful clinical technique(s) that add to the body of knowledge of clinical implant dentistry
• Case reports (1-3 subjects) – submit as an ePoster only
• Case series (3-20 subjects) – submit as an ePoster only

These submissions should consist of science-based presentations on original, novel and thoughtful clinical techniques, biomaterials and devices that add to the body of knowledge of clinical implant dentistry.

Presenters are allotted seven (7) minutes for presentation followed by three minutes of discussion.

All Oral Research and Clinical Innovations presentations are scheduled for Friday, March 28, 2025.

Original studies, clinical innovations with limited data or literature review-based clinical cases, as well as meta-analysis, should be submitted only as an ePoster.

Submissions not accepted for Oral Research Presentations will be eligible for presentation as an ePoster.

ePoster Presentations (unlimited accepted):

1. Scientific Research
2. Clinical Research
3. Systematic Reviews including meta-analysis (posters only)
4. Case Studies (posters only)

ePoster Presentations are scheduled in the Exhibit Hall on:
Thursday, March 27, 12:10 – 1:00 pm, 5:45 – 7:15 pm;
Friday, March 28, Noon – 1:30 pm

ePoster abstract submissions are due October 25th. However, the actual ePoster slides (5 maximum) which will be presented at the meeting are due January 2025. Additional information regarding final ePoster submissions will be sent following the October 25th deadline.

All ePosters accepted for presentation at AO’s 2025 Annual Meeting will be displayed on large monitors in the exhibit area as PowerPoint or Keynote slides. Authors will be assigned a 10-minute display time and must be present to answer questions from the ePoster Committee and attendees during their assigned time. All ePoster presenters are expected to pay the meeting registration fee and present in-person in Seattle. No virtual presentations are allowed.

Assigned display times will be provided to the presenter in December 2024. The final ePoster slides will remain on the AO website indefinitely so they may be viewed before, during and after the meeting.

Please CLICK HERE to view the 2024 AO Annual Meeting ePoster Submissions.
https://epostersonline.com/osseo2024/

The introduction should consist of two or three brief sentences and contain the reason the study was initiated and what the object of the study was (what could be gained). The introduction should clearly state whether this is a research study or pilot project with limited data.

A description of the methods necessary to evaluate the study must be included (i.e., retrospective chart review, prospective trial, etc.). Detailed descriptions of laboratory techniques should not be included (i.e., measurements were made of calcium, phosphate and creatinine).

The results are expected to compose 1/2 to 2/3 of the abstract and specific data necessary to evaluate the abstract should be included. Include any additional data you believe would enhance the abstract. Statements to the effect: “…data will be discussed at the presentation” are grounds for refusal of the abstract. Statistical analysis must be included for Oral Clinical/Scientific Research presentations. Statistical analysis should be included for Clinical Innovations presentations when appropriate. Statistical analysis may be included (where indicated) for ePoster presentation.

The conclusion should be no more than two or three sentences indicating the significance of the results in terms of what was originally designed.

1. Why you did the study
2. How it was done
3. What you found
4. What is the importance of your findings

• High commercial influence – please use generic names whenever possible
• Previously reported/published study
• Too little data
• Inadequate controls
• Methods of the study not indicated
• Insignificant study
• Poorly written presentation including improper spelling grammar
• Conclusion is questionable in relationship to data presented

• All presenters of the accepted abstracts are expected to register for the meeting.
• Do not submit work previously submitted for publication or presented at other meetings. Previously published or presented work will not be considered.
• Abstracts reporting experiments on human subjects require written authorization from an Institutional Review Board (IRB).
• Abstracts reporting experiments on animals require written authorization from an animal use committee.
• Case presentations that describe routine laboratory tests and/or routing therapy do not require IRB approval; However, if a patient has been treated with an investigative drug or device, IRB approval is required.
• Specific company information should not be listed or mentioned within the abstract. Generic product terms should be used whenever possible.
• All authors whose names appear on the abstract must have approved its submission to AO for possible presentation and online display.
• There is a 2,500-character limit (including spaces) on the body of the abstract which includes all sections.
• Abstracts accepted for presentation at the Annual Meeting will be displayed exactly as submitted.
• Expenses associated with the submission and preparation of an abstract are the responsibility of the presenter.
• Please confirm spelling, use proper vocabulary and grammar when writing your abstract.
• The AO may feature submissions and presentations on its website or through other media or education modules.
• All abstracts must be submitted online no later than 11:59 pm on Friday, October 20, 2023.